NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GHRS

GH Research PLC

Apr 25 • 04:00PM ET

9.53

Dollar change +0.03
Percentage change 0.32	%

Healthcare • Biotechnology • Ireland • NASD

Peers: NBIX EXEL CORT SAGE ALT AGIO URGN VKTX MNKD PRTA

| Held by: PSIL ONEQ EIRL GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	34.80%	Shs Outstand	52.03M	Perf Week	4.73%
Market Cap	591.13M	Forward P/E	-	EPS next Y	-1.53	Insider Trans	0.00%	Shs Float	40.44M	Perf Month	-20.98%
Income	-38.96M	PEG	-	EPS next Q	-0.36	Inst Own	51.02%	Short Float	7.12%	Perf Quarter	7.93%
Sales	0.00M	P/S	-	EPS this Y	-35.00%	Inst Trans	9.34%	Short Ratio	5.46	Perf Half Y	14.82%
Book/sh	3.44	P/B	2.77	EPS next Y	-50.99%	ROA	-18.80%	Short Interest	2.88M	Perf Year	-15.66%
Cash/sh	2.41	P/C	3.96	EPS next 5Y	-28.09%	ROE	-19.58%	52W Range	6.00 - 20.50	Perf YTD	36.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-179.37%	ROI	-21.73%	52W High	-53.51%	Beta	0.88
Dividend TTM	-	Quick Ratio	17.23	Sales past 5Y	0.00%	Gross Margin	-	52W Low	58.83%	ATR (14)	0.76
Dividend Ex-Date	-	Current Ratio	17.23	EPS Y/Y TTM	-9.46%	Oper. Margin	-	RSI (14)	44.82	Volatility	5.91% 8.43%
Employees	50	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	34.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	21.92%	Payout	-	Rel Volume	0.16	Prev Close	9.50
Sales Surprise	-	EPS Surprise	25.46%	Sales Q/Q	-	Earnings	Feb 27 BMO	Avg Volume	527.39K	Price	9.53
SMA20	-0.33%	SMA50	-12.20%	SMA200	-1.81%	Trades		Volume	82,928	Change	0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Guggenheim	Buy	$32
Mar-07-25	Initiated	RBC Capital Mkts	Outperform	$31
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight	$14
Aug-16-22	Initiated	H.C. Wainwright	Buy	$45
Jun-16-22	Initiated	ROTH Capital	Buy	$66

Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-13-25 05:30PM	Guggenheim starts GH Research at Buy, sees long-term upside potential (TipRanks)
Mar-03-25 11:06AM	Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 (Insider Monkey) -9.08%
11:00AM	Loading…
Mar-01-25 11:00AM	GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-27-25 07:00AM	GH Research Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 01:49PM	GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 (Insider Monkey)
Feb-04-25 08:52PM	GH Research Announces Pricing of $150 Million Public Offering (GlobeNewswire) -9.31% -8.06%
Feb-03-25 08:22PM	Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 (Insider Monkey) +69.72%
04:03PM	GH Research Announces Proposed Public Offering (GlobeNewswire)
07:07AM	Shares of psychedelics biotech nearly double on depression data (BioPharma Dive)
07:00AM	GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction (GlobeNewswire)
Jan-31-25 04:01PM	GH Research to Provide Update on Phase 2b Trial with GH001 in TRD (GlobeNewswire) +9.39%
07:00AM	Loading…
Jan-10-25 07:00AM	GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents (GlobeNewswire)
Nov-20-24 09:55AM	Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? (Zacks) +13.94%
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 07:00AM	GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-09-24 12:00PM	GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:35AM	After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS) (Zacks)
Sep-08-24 09:14PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-03-24 07:05AM	GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.57%
07:00AM	GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer (GlobeNewswire)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-03-24 09:48AM	Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns (InvestorPlace)
May-13-24 08:50AM	Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why (Zacks)
May-10-24 09:55AM	Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know (Zacks) +6.84%
May-03-24 01:53PM	GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
09:55AM	Loading…
Mar-05-24 09:55AM	How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% (Zacks)
Feb-29-24 07:00AM	GH Research Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +7.90%
Jan-18-24 04:30PM	GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression (GlobeNewswire)
Jan-16-24 09:55AM	Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -7.32%
Dec-19-23 11:07AM	15 Best Falling Stocks To Buy Now (Insider Monkey) +9.13%
Nov-09-23 04:45PM	GH Research Reports Third Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Sep-29-23 04:45PM	GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression (GlobeNewswire)
Aug-23-23 07:00AM	GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-17-23 11:53AM	Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation (Simply Wall St.)
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
May-11-23 07:30AM	GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks) +14.78%
Mar-12-23 12:22PM	10 Best Psychedelic Stocks to Buy According to Hedge Funds (Insider Monkey)
Mar-02-23 07:00AM	GH Research Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-07-23 10:15AM	GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-09-23 07:30AM	GH Research Provides Business Updates and Highlights Key Upcoming Milestones (GlobeNewswire) -13.00%
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace) -6.67%
Nov-10-22 07:05AM	GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +7.03%
Sep-14-22 09:55AM	Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High? (Zacks) +9.26%
Aug-30-22 03:02PM	7 Psychedelics Stocks to Buy for a Big Drug Boom (InvestorPlace) -6.01%
Aug-29-22 09:55AM	Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know (Zacks) +7.95%
Aug-23-22 07:00AM	GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +5.33%
May-18-22 07:00AM	GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -9.98%
Mar-28-22 07:04AM	GH Research Reports Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-24-22 11:48AM	We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate (Simply Wall St.)
Dec-06-21 07:10AM	GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire) +21.86%
07:00AM	GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression (GlobeNewswire)
Oct-27-21 04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey) +10.61%
Sep-25-21 10:07AM	We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-23-21 05:25PM	GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-02-21 04:20PM	Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies (Benzinga) -5.64%
Jun-25-21 01:23PM	7 Companies Go Public Today. What Investors Need to Know. (Barrons.com)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GHRS

GH Research PLC

Upgrade your FINVIZ experience